Skip to main content
Log in

Active components from Lagotis brachystachya maintain uric acid homeostasis by inhibiting renal TLR4-NLRP3 signaling in hyperuricemic mice

  • Original Article
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

Lagotis brachystachya Maxim is a herb widely used in traditional Tibetan medicine. Our previous study indicated that total extracts from Lagotis brachystachya could lower uric acid levels. This study aimed to further elucidate the active components (luteolin, luteoloside and apigenin) isolated from Lagotis brachystachya and the underlying mechanism in vitro and in vivo. The results showed that treatment with luteolin and luteoloside reversed the reduction of organic anion transporter 1 (OAT1) levels, while apigenin attenuated the elevation of urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) levels in uric acid-treated HK-2 cells, which was consistent with the finding in the kidneys of potassium oxonate (PO)-induced mice. On the other hand, hepatic xanthine oxidase activity was inhibited by the components. In addition, all of these active components improved the morphology of the kidney in hyperuricemic mice. Moreover, molecular docking showed that luteolin, luteoloside and apigenin could bind Toll-like receptor 4 (TLR4) and NLR family pyrin domain containing 3 (NLRP3). Congruently, western blot analysis showed that the components inhibited TLR4/myeloid differentiation primary response 88 (MyD88)/NLRP3 signaling. In conclusion, these results indicated that luteolin, luteoloside and apigenin could attenuate hyperuricemia by decreasing the production and increasing the excretion of uric acid, which were mediated by inhibiting inflammatory signaling pathways.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Data availability

Data will be made available on reasonable request.

References

  • Amezcua-Castillo LM, Juarez-Vicuna Y, Marquez-Velasco R, Amezcua-Guerra LM (2020) Activation status of NLRP3 Inflammasome in peripheral blood mononuclear cells from patients with Gout flare. J Clin Rheumatol 26:S208–S212

    Article  Google Scholar 

  • Anzai N, Endou H (2011) Urate transporters: an evolving field. Semin Nephrol 31:400–409

    Article  CAS  Google Scholar 

  • Azevedo VF, Kos IA, Vargas-Santos AB, da Rocha Castelar PG, Dos Santos Paiva E (2019) Benzbromarone in the treatment of gout. Adv Rheumatol 59:37

    Article  Google Scholar 

  • De Nardo D, Latz E (2011) NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol 32:373–379

    Article  Google Scholar 

  • Dong Y, Zhao T, Ai W, Zalloum WA, Kang D, Wu T, Liu X, Zhan P (2019) Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016–2019). Expert Opin Ther Pat 29:871–879

    Article  CAS  Google Scholar 

  • Fan SH, Wang YY, Lu J, Zheng YL, Wu DM, Li MQ, Hu B, Zhang ZF, Cheng W, Shan Q (2014) Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome. PLoS ONE 9:e89961

    Article  Google Scholar 

  • Guo LF, Chen X, Lei SS, Li B, Zhang NY, Ge HZ, Yang K, Lv GY, Chen SH (2020) Effects and mechanisms of Dendrobium officinalis six Nostrum for treatment of Hyperuricemia with Hyperlipidemia. Evid-Based Complement Alternate Med 2020:2914019

    Google Scholar 

  • Kanbay M, Solak Y, Afsar B, Nistor I, Aslan G, Caglayan OH, Aykanat A, Donciu MD, Lanaspa MA, Ejaz AA, Johnson RJ, Covic A (2017) Serum uric acid and risk for acute kidney injury following contrast. Angiology 68:132–144

    Article  CAS  Google Scholar 

  • Li Q, Tian Z, Wang M, Kou J, Wang C, Rong X, Li J, Xie X, Pang X (2019) Luteoloside attenuates neuroinflammation in focal cerebral ischemia in rats via regulation of the PPARgamma/Nrf2/NF-kappaB signaling pathway. Int Immunopharmacol 66:309–316

    Article  CAS  Google Scholar 

  • Lim H, Min DS, Park H, Kim HP (2018) Flavonoids interfere with NLRP3 inflammasome activation. Toxicol Appl Pharmacol 355:93–102

    Article  CAS  Google Scholar 

  • Lin WQ, Xie JX, Wu XM, Yang L, Wang HD (2014) Inhibition of xanthine oxidase activity by gnaphalium affine extract. Chin Med Sci J 29:225–230

    Article  Google Scholar 

  • Luan RL, Meng XX, Jiang W (2016) Protective effects of Apigenin against Paraquat-induced acute lung injury in mice. Inflammation 39:752–758

    Article  CAS  Google Scholar 

  • Ma C, Yang X, Lv Q, Yan Z, Chen Z, Xu D, Liu X, Yang W, Xing S (2020) Soluble uric acid induces inflammation via TLR4/NLRP3 pathway in intestinal epithelial cells. Iran J Basic Med Sci 23:744–750

    PubMed  PubMed Central  Google Scholar 

  • Nishitani Y, Yamamoto K, Yoshida M, Azuma T, Kanazawa K, Hashimoto T, Mizuno M (2013) Intestinal anti-inflammatory activity of luteolin: role of the aglycone in NF-kappaB inactivation in macrophages co-cultured with intestinal epithelial cells. BioFactors 39:522–533

    Article  CAS  Google Scholar 

  • Otani N, Ouchi M, Hayashi K, Jutabha P, Anzai N (2017) Roles of organic anion transporters (OATs) in renal proximal tubules and their localization. Anat Sci Int 92:200–206

    Article  CAS  Google Scholar 

  • Pavelcova K, Bohata J, Pavlikova M, Bubenikova E, Pavelka K, Stiburkova B (2020) Evaluation of the influence of genetic variants of SLC2A9 (GLUT9) and SLC22A12 (URAT1) on the development of hyperuricemia and Gout. J Clin Med 9:2510

    Article  CAS  Google Scholar 

  • Rahmi EP, Kumolosasi E, Jalil J, Husain K, Buang F, Abd Razak AF, Jamal JA (2020) Anti-hyperuricemic and anti-inflammatory effects of Marantodes pumilum as potential treatment for Gout. Front Pharmacol 11:289

    Article  CAS  Google Scholar 

  • Romero CA, Remor A, Latini A, De Paul AL, Torres AI, Mukdsi JH (2017) Uric acid activates NRLP3 inflammasome in an in-vivo model of epithelial to mesenchymal transition in the kidney. J Mol Histol 48:209–218

    Article  CAS  Google Scholar 

  • Serrano JL, Figueiredo J, Almeida P, Silvestre S (2020) From Xanthine oxidase inhibition to in vivo hypouricemic effect: an integrated overview of in vitro and in vivo studies with focus on natural molecules and analogues. Evid-Based Complement Alternat Med 2020:9531725

    Article  Google Scholar 

  • Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O’Hanlon CE, Tariq A, Okunogbe A, Han D, Shanman R (2017) Management of Gout: a systematic review in support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med 166:37–51

    Article  Google Scholar 

  • Shen R, Ma L, Zheng Y (2020) Anti-inflammatory effects of luteolin on acute gouty arthritis rats via TLR/MyD88/NF-kappaB pathway. Zhong Nan Da Xue Xue Bao Yi Xue Ban 45:115–122

    PubMed  Google Scholar 

  • So A (2007a) New knowledge on the pathophysiology and therapy of gout. Z Rheumatol 66(562):564–567

    Google Scholar 

  • So A (2007b) Recent advances in the pathophysiology of hyperuricemia and gout. Rev Med Suisse 3(720):722–724

    Google Scholar 

  • Su HY, Yang C, Liang D, Liu HF (2020) Research advances in the mechanisms of hyperuricemia-induced renal injury. Biomed Res Int 2020:5817348

    PubMed  PubMed Central  Google Scholar 

  • Torres RJ, Puig JG (2018) GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease. Int J Rheum Dis 21:1270–1276

    Article  CAS  Google Scholar 

  • Tsai CW, Lin SY, Kuo CC, Huang CC (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS ONE 12:e0170393

    Article  Google Scholar 

  • Wang K, Hu L, Chen JK (2018) RIP3-deficience attenuates potassium oxonate-induced hyperuricemia and kidney injury. Biomed Pharmacother 101:617–626

    Article  CAS  Google Scholar 

  • Xiong W, Zhang H, Wen L, Wang X, Zhong G, Shi Y, DU, X. and Zhu, J. (2018) Effect of Lagotis brachystachya Maxim extract on xanthine oxidase and renal urate transporters in hyperuricemia mice. Chin J New Drugs 27:1538–1543

    Google Scholar 

  • Xu L, Shi Y, Zhuang S, Liu N (2017) Recent advances on uric acid transporters. Oncotarget 8:100852–100862

    Article  Google Scholar 

  • Yamagata K, Hashiguchi K, Yamamoto H, Tagami M (2019) Dietary Apigenin reduces induction of LOX-1 and NLRP3 expression, Leukocyte Adhesion, and Acetylated low-density lipoprotein uptake in human endothelial cells exposed to Trimethylamine-N-Oxide. J Cardiovasc Pharmacol 74:558–565

    Article  CAS  Google Scholar 

  • Yan J, Zhang G, Hu Y, Ma Y (2013) Effect of luteolin on xanthine oxidase: inhibition kinetics and interaction mechanism merging with docking simulation. Food Chem 141:3766–3773

    Article  CAS  Google Scholar 

  • Zhang X, Yang X, Wang M, Li X, Xia Q, Xu S, Xu J, Cai G, Wang L, Xin L, Zou Y, Pan F (2016) Association between SLC2A9 (GLUT9) gene polymorphisms and gout susceptibility: an updated meta-analysis. Rheumatol Int 36:1157–1165

    Article  CAS  Google Scholar 

  • Zhu J, Shi Y, Cheng H, Wang H, Wang R, Li M (2019) Chemical constituents from Lagotis brachystachy. J Chin Med Mater 42:552–555

    Google Scholar 

Download references

Funding

The project was supported by grants from the National Natural Science Foundation of China (No. 82060757), the Science and Technology Research Project of Jiangxi Provincial Department of Education (No. GJJ190632) and the Science and Technology Project of Jiangxi Provincial Administration of Traditional Chinese Medicine (No. 2019A004, 2019A258).

Author information

Authors and Affiliations

Authors

Contributions

J.Z., H.C. and L.Y. conceived of the project. J.Z., H.Y., W.H. and J.C. performed the experiments. J.Z., and Y.L. analyzed data. L.Y. did molecular docking. J.Z., H.C. and L.Y. wrote and revised the manuscript. All authors read and approved the submission.

Corresponding authors

Correspondence to Li-Tao Yi or Hong-Yu Cheng.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All animal procedure was in accordance with guidelines from China Council on Animal Care and was approved by the Animal Commission of Jiangxi University of Chinese Medicine (No. JZLLSC2019-0221 on 2019/02/28).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, JX., Yang, HY., Hu, WQ. et al. Active components from Lagotis brachystachya maintain uric acid homeostasis by inhibiting renal TLR4-NLRP3 signaling in hyperuricemic mice. Inflammopharmacol 29, 1187–1200 (2021). https://doi.org/10.1007/s10787-021-00844-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-021-00844-5

Keywords

Navigation